DNA vaccine against oncogenic hamster cells transformed by HPV16 E6/E7 oncogenes and the activated ras oncogene

Oncology Reports

Volumn 6, Issue 1, 1999, Pages 211-215

  Smahel, Michal ^a   Sobotkova, Eva ^a   Vonka, Vladimir ^a   Hamsikova, Eva ^a   Zak, Roman ^a   Kitasato, Hidero ^b   Ludvikova, Viera ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA vaccine; H ras; Human papillomavirus

Indexed keywords

1,2 DIOLEOYLOXY 3 (TRIMETHYLAMMONIUM)PROPANE; 1,2-DIOLEOYLOXY-3-(TRIMETHYLAMMONIUM)PROPANE; CANCER VACCINE; DNA VACCINE; DRUG CARRIER; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HYBRID PROTEIN; MONOUNSATURATED FATTY ACID; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; QUATERNARY AMMONIUM DERIVATIVE; REPRESSOR PROTEIN;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL LINE; EVALUATION; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HAMSTER; HUMAN; IMMUNIZATION; IMMUNOLOGY; ONCOGENE; ONCOGENE RAS; PAPILLOMA VIRUS; SYRIAN HAMSTER; VIRUS CELL TRANSFORMATION;

ANIMALS; CANCER VACCINES; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CRICETINAE; DRUG CARRIERS; EVALUATION STUDIES; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENES, RAS; HUMANS; IMMUNIZATION; MESOCRICETUS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; ONCOGENES; PAPILLOMAVIRIDAE; QUATERNARY AMMONIUM COMPOUNDS; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; VACCINES, DNA;

EID: 0032622217     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.6.1.211     Document Type: Article

References (39)

1. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54: 594-606, 1993.
2. zur Hausen H and de Villiers EM: Human papillomaviruses. Annu Rev Microbiol 48: 427-447, 1994.
3. van den Brule AJC, Snijders PJF. Meijer CJLM and Walboomers JMM: PCR based detection of genital HPV genotypes: an update and future perspectives. Papillomavirus Rep 4: 95-99, 1993.
4. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R and Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802, 1995.
5. van Driel WJ, Ressing ME, Brandt RM, Toes RE, Fleuren GJ, Trimbos JB, Kast WM and Melief CJ: The current status of therapeutic HPV vaccine. Ann Med 28: 471-477, 1996.
6. Tindle RW: Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol 8: 643-650, 1996.
7. Vonka V: Human papillomavirus vaccines. Folia Biol Praha 42: 73-78, 1996.
8. Chen LP, Thomas EK, Hu SL, Hellstrom I and Hellstrom KE: Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 88: 110-114, 1991.
9. Chen L, Mizuno MT, Singhal MC, Hu SL, Galloway DA, Hellstrom I and Hellstrom KE: Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 148: 2617-2621, 1992.
10. Ulmer JB, Donnelly JJ and Liu MA: Toward the development of DNA vaccines. Curr Opin Biotechnol 7: 653-658, 1996.
11. Donnelly JJ, Ulmer JB, Shiver JW and Liu MA: DNA vaccines. Annu Rev Immunol 15: 617-648, 1997.
12. Conry RM, LoBuglio AF and Curiel DT: Polynucleotide-mediated immunization therapy of cancer. Semin Oncol 23: 135-147, 1996.
13. Bright RK, Beames B, Shearer MH and Kennedy RC: Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Cancer Res 56: 1126-1130, 1996.
14. Schirmbeck R, Bohm W and Reimann J: DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. J Immunol 157: 3550-3558, 1996.
15. Hofland H and Huang L: Inhibition of human ovarian carcinoma cell proliferation by liposome-plasmid DNA complex. Biochem Biophys Res Commun 207: 492-496, 1995.
16. Símová J. Bubeník J. Rössner P, Bubeníková D and Jandlová T: Tumour inhibitory effects of plasmid DNA. Oncol Rep 4: 1161-1163, 1997.
17. Messina JP, Gilkeson GS and Pisetsky DS: Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 147: 1759-1764, 1991.
18. Yamamoto S, Yamamoto T, Shimada S, Kuramoto E. Yano O, Kataoka T and Tokunaga T: DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 36: 983-997, 1992.
19. Pisetsky DS, Reich C, Crowley SD and Halpern MD: Immunological properties of bacterial DNA. Ann NY Acad Sci 772: 152-163, 1995.
20. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz VI, Carson DA and Raz E: Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273: 352-354, 1996.
21. Klinman DM, Yamshchikov G and Ishigatsubo Y: Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158: 3635-3639, 1997.
22. Kitasato H, Vonka R, Bostik P, Hamsikova E, Sobotkova E, Smahel M and Vonka V: Properties of Syrian hamster cells transformed by human papillomavirus type 16, Acta Virol 40: 281-288, 1996.
23. Vousden KH, Doniger J, DiPaolo JA and Lowy DR: The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res 3: 167-175, 1988.
24. Shin C and Weinberg RA: Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29: 161-169, 1982.
25. Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR and Chang EH: Mechanism of activation of a human oncogene. Nature 300: 143-149, 1982.
26. Abrams SI, Hand PH, Tsang KY and Schlom J: Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 23: 118-134, 1996.
27. McLachlan G, Davidson DJ, Stevenson BJ, Dickinson P, Davidson-Smith H, Dorin JR and Porteous DJ: Evaluation in vitro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy. Gene Ther 2: 614-622, 1995.
28. Ghoumari AM, Rixe O, Yarovoi SV, Zerrouqi A, Mouawad R, Poynard T, Opolon P, Khayat D and Soubrane C: Gene transfer in hepatocarcinoma cell lines: in vitro optimization of a virus-free system. Gene Ther 3: 483-490, 1996.
29. Alexander MY and Akhurst RJ: Liposome-medicated gene transfer and expression via the skin. Hum Mol Genet 4: 2279-2285, 1995.
30. McLachlan G, Ho LP, Davidson-Smith H, Samways J, Davidson H, Stevenson BJ, Carothers AD, Alton EW, Middleton PG, Smith SN, Kallmeyer G, Michaelis U, Seeber S, Naujoks K, Greening AP, Innes JA, Dorin JR and Porteous DJ: Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP. Gene Ther 3: 1113-1123, 1996.
31. Porteous DJ, Dorin JR, McLachlan G, Davidsonsmith H, Davidson H, Stevenson BJ, Carothers AD, Wallace WAH, Moralce S, Hoenes C, Kallmeyer G, Michaelis U, Naujoks K, Ho LP, Samways JM, Imrie M, Greening AP and Innes JA: Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 4: 210-218, 1997.
32. Sedegah M, Hedstrom R, Hobart P and Hoffman SL: Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 91: 9866-9870, 1994.
33. + T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur J Immunol 25: 2588-2597, 1995.
34. Fenton RG, Taub DD, Kwak LW, Smith MR and Longo DL: Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst 85: 1294-1302, 1993.
35. Ebert R, Wiseman RW, Barrett JC, Reiss E, Rollich G and Schiffmann D: Characterization of the Syrian hamster c-Ha-ras gene and intron-D-exon transcript. Mol Carcinog 5: 254-258, 1992.
36. Riou G, Barrois M, Sheng ZM, Duvillard P and Lhomme C: Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers. Oncogene 3: 329-333, 1988.
37. Tate JE, Mutter GL, Prasad CJ, Berkowitz R, Goodman H and Crum CP: Analysis of HPV-positive and -negative vulvar carcinomas for alterations in c-myc. Ha-, Ki-, and N-ras genes. Gynecol Oncol 53: 78-83, 1994.
38. Anwar K, Nakakuki K, Naiki H and Inuzuka M: ras gene mutations and HPV infection are common in human laryngeal carcinoma. Int J Cancer 53: 22-28, 1993.
39. Spandidos DA, Sourvinos G and Koffa M: ras genes, p53 and HPV as prognostic indicators in human cancer, Oncol Rep 4: 211-218, 1998.